Environment and Breast Cancer: Science Review


Search the Mammary Carcinogens Reviews Database

hydrazine
CAS RN 302-01-2



Cancer studies: Experimental details
 
Print this page
Steinhoff D, Mohr U, Schmidt WM. On the question of the carcinogenic action of hydrazine--evaluation on the basis of new experimental results. Exp Pathol 1990;39(1):1-9.
Notes
A study listed by CPDB 2005 that did not report mammary tumors.
Route
Route of chemical administration: dermal, inhalation, gavage (delivery directly into the stomach), in feed, subcutaneous injection (under the skin), or intraperitoneal injection (into the cavity that contains the abdominal organs).
in drinking water
Species
Mostly rat or mouse, though some studies use hamster or monkeys.
Mice
Sexes
F for female, M for male.
F, M
Strain
Strain information for the animal species used in the study.
Bor:NMRI, SPF-bred NMRI
Doses
Dosage, frequency, and duration of treatment; the sizes of the groups of animals involved and what age the animals were at the beginning of the study.
For 2 yrs
Time after cessation of dosing
How long the animals were observed after the chemical was no longer being administered and before death of the animals.
none
Comments
This field contains information on the survival rates of the animals and the body weight trends in order to evaluate whether these factors were likely to have affected the generation of mammary gland tumors. Mammary gland tumors tend to develop later in an animal’s life, so studies with lowered survival could mean that animals died before mammary gland tumors could develop. Decreased weight (perhaps due to toxicity of the chemical) can decrease the development of tumors. This field may also contain other comments about the design or outcome of the study.
Total tumor bearing animals were similar (approaching half of the group) in controls and dosed groups.
CPDB TD50 (mg/kg-d)
Data excerpted from the CPDB database that is defined as the "dose-rate in mg/kg body wt/day which, if administered chronically for the standard lifespan of the species, will halve the probability of remaining tumorless throughout that period". The CPDB calculated values for all tumor endpoints listed as well as for total tumors. The range of mammary gland tumors TD50s is provided, as well as an overall range.
Overall: 58.5